BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, May 13, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 28, 2018
View Archived Issues
Lundbeck initiates phase I study with Lu-AF-28996 for Parkinson's disease
Read More
Rigel announces the initiation of phase I trial of R-835
Read More
How targeted therapies are lost in translation
Read More
Increasing the specificity of kappa-opioid agonists
Read More
Dzuveo approved in Europe
Read More
FDA grants priority review for glasdegib in previously untreated acute myeloid leukemia
Read More
Vamorolone demonstrates improvements in strength and endurance in boys with DMD
Read More
First patient dosed in phase II study of REL-1017 in patients with major depressive disorder
Read More
FDA grants orphan drug designation for cannabidiol as treatment of autoimmune hepatitis
Read More
PharmaMar and Chugai announce early termination of the license agreement for Zepsyre in Japan
Read More
Preliminary data from phase Ib/II study of PCM-075 in combination with cytarabine or decitabine
Read More
Positive topline data presented from phase II/III study of CR-845
Read More
Results presented for KEYNOTE-046 study of ADXS-PSA plus pembrolizumab in patients with mCRPC
Read More
Aldeyra announces additional clinical programs planned for next year
Read More
Roivant creates new business units and launches Altavant Sciences
Read More
Part A data from phase III HOPE study of voxelotor in sickle cell disease show primary endpoint met
Read More
MSDC-5514 - a novel insulin sensitizer to treat diabetes and nonalcoholic steatohepatitis
Read More
FDA approves Braftovi + Mektovi for unresectable or metastatic melanoma
Read More
Omeros obtains approvals to begin phase I trial with PDE7 inhibitor OMS-527
Read More
Medivir reports promising topline results from phase IIa extension study of MIV-711
Read More
Gachon University, Seoul National University identify SIRT1 activators
Read More
Vertex patents CFTR modulators
Read More
FDA grants priority review to Jazz's pediatric sNDA for Xyrem
Read More
Microtubule-specific brain-penetrating PET imaging agent [11C]HD-800 characterized
Read More
ExCellThera completes phase I/II trial of ECT-001 technology in leukemia
Read More
Benefits seen with MEDI-0382 in overweight/obese subjects with type 2 diabetes
Read More
Alexion seeks E.U. approval for ALXN-1210 for PNH
Read More